Results 181 to 190 of about 40,837 (237)

Renin‐Angiotensin System Inhibitor Use and Mortality in Older Hypertensive Patients With and Without Dementia: A Nationwide Registry‐Based Cohort Study

The Journal of Clinical Hypertension, Volume 28, Issue 8, August 2026.
ABSTRACT Cardiovascular risk factors are often undertreated in patients with dementia. Renin‐angiotensin system inhibitors (RASI) are first‐line treatments for hypertension. We examined the association between RASI and all‐cause mortality in hypertensive patients with and without dementia, comparing angiotensin‐converting enzyme inhibitors (ACEI) to ...
Marta Villa Lopez, Minh Tuan Hoang, Hong Xu, Jakob Norgren, Bojana Petek, Juraj Secnik, Irena Kalar, Dorota Religa, Silvia Maioli, Minjia Mo, Ingemar Kåreholt, Kristina Johnell, Maria‐Luz Cuadrado, Maria Eriksdotter, Sara Garcia‐Ptacek   +14 more
wiley   +1 more source

Safety and tolerability of the ACE-inhibitor lisinopril among Nigerian adults with HIV: preliminary pilot data from a randomized clinical trial. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Dankishiya FS, Muhammad H, Wudil UJ, Musa BM, Du L, Adam IA, Ahonkhai AA, Burgner AM, Nalado AM, Sani MU, Abdu A, Shepherd BE, Aliyu MH, Wester CW.   +13 more
europepmc   +1 more source

Potassium binders and continuation of renin–angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)

Journal of Internal Medicine, Volume 300, Issue 2, Page 179-192, August 2026.
Abstract Introduction Hyperkalaemia is a serious complication in patients with chronic kidney disease (CKD) and heart failure (HF), often leading to the discontinuation of renin–angiotensin–aldosterone system inhibitors (RAASi; renin‐angiotensin system inhibitors [RASi] and mineralocorticoid receptor antagonists [MRAs]) despite their cardiorenal ...
Hans Furuland, Anders Olof Larsson, Milica Uhde, Kristel Parv, Matilda Almstedt, Thomas Cars, Maria K. Svensson   +6 more
wiley   +1 more source

Primary care Adherence to Heart failure guidelines in post-discharge, evaluation & routine management (PATHFINDER): a randomized controlled trial. [PDF]

ESC Heart Fail
Maiorana A, Dai L, Dorje T, Gootjes J, Shah A, Dembo L, Hillis GS, Jacques A, Chih H, Rankin J, Atherton JJ, Robinson S, Reid CM.   +12 more
europepmc   +1 more source

Persistent Haematuria Is Associated With Reduced Kidney Survival in Primary Podocytopathies

Nephrology, Volume 31, Issue 8, August 2026.
ABSTRACT Aim Haematuria is frequently present in podocytopathies, but its significance and prognostic value are not well described. This study aimed to determine the prevalence and association between persistent haematuria and kidney survival in patients with membranous nephropathy (MN), minimal change disease (MCD) and focal segmental ...
Gabriel Ștefan, Nicoleta Petre, Adrian Zugravu, Simona Stancu   +3 more
wiley   +1 more source

Are Angiotensin-Converting Enzyme Inhibitors Effective in the Treatment of Hypertension in Black Patients? [PDF]

CJC Open
Nkunu V, Campbell L, Tsuyuki RT, Bello AK, Ringrose J.   +4 more
europepmc   +1 more source

Cardiovascular Outcomes With SGLT‐2 Inhibitors in Patients With Type 2 Diabetes and Obstructive Sleep Apnoea: A Real‐World Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7607-7610, August 2026.
Reuben L. Odai, Dennis Dela Tsagli, Anthony Alchaer, Laiba Sajjad, Kwame Adjei‐Sefah, Chukwuemeka Aghasili, Smith Frimpong, Hussam Farhoud   +7 more
wiley   +1 more source

Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes. [PDF]

Front Cardiovasc Med
Li J, Tang C.
europepmc   +1 more source

Ten years real-world experience with sacubitril/valsartan in patients with heart failure with reduced ejection fraction. [PDF]

ESC Heart Fail
Savarese G, Basile C, Mebazaa A, Bayes-Genis A, Kang SM, Yoo BS, Eid C, Bozkurt B, Butler J.   +8 more
europepmc   +1 more source